Annexon to Present at the Bank of America Securities Health Care Conference 2026

Annexon (Nasdaq: ANNX) will present at the Bank of America Securities Health Care Conference on May 13, 2026 at 11:20 a.m. PT.

Rhea-AI Summary

Annexon (Nasdaq: ANNX) will present at the Bank of America Securities Health Care Conference on May 13, 2026 at 11:20 a.m. PT. Douglas Love, President and CEO, will deliver the presentation.

A live webcast is available via the company Investors page and a replay will be archived for 30 days.

Argus May 6 session

-0.35% close to close Open Argus

Details

News Market Reaction – ANNX

On May 6, the day this news came out, ANNX closed 0.35% below the previous close.

Data tracked by StockTitan Argus for the May 6 session.

Market Context

This announcement adds another investor conference appearance to Annexon’s ongoing outreach, followi...

Analysis

This announcement adds another investor conference appearance to Annexon’s ongoing outreach, following prior events in February and April 2026. The company enters the Bank of America conference with shares above the 200-day MA of $4.28 and a recent update citing $238.3 million in cash and short-term investments and a 2025 net loss of $208.5 million. Investors may monitor progress of late-stage programs, capital-raising flexibility from share authorization proposals, and upcoming ARCHER II Phase 3 milestones.

Key Figures

Cash & short-term investments: $238.3 million Net loss: $208.5 million R&D expenses: $184.7 million +5 more

Cash & short-term investments

$238.3 million

As of December 31, 2025

Net loss

$208.5 million

Full-year 2025 net loss

R&D expenses

$184.7 million

Research and development expenses for 2025

G&A expenses

$31.7 million

General and administrative expenses for 2025

EPS

$1.34 loss per share

2025 net loss attributable to common stockholders

Authorized common stock

300,000,000 shares

Current authorized common shares per proxy

Proposed authorized shares

500,000,000 shares

Proposed increase in authorized common stock

Shares outstanding

162,507,278 shares

Outstanding as of April 13, 2026

Historical Context

5 past events · Latest: Apr 08

5 events

1. Apr 08

   Investor conference

   24h Move

   +1.5%

   Needham Virtual Healthcare Conference presentation and webcast details.

2. Mar 30

   Earnings and pipeline

   24h Move

   +11.7%

   Q4 and 2025 results with cash runway and key 2026 milestones.

3. Mar 16

   Inducement grant

   24h Move

   -1.9%

   Equity inducement option grant to a new employee under award plan.

4. Feb 24

   Investor conference

   24h Move

   +1.4%

   TD Cowen health care conference presentation and webcast information.

5. Feb 17

   KOL event

   24h Move

   +3.1%

   KOL event on vonaprument and ARCHER II Phase 3 trial in GA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biopharmaceutical, immunotherapies, neuroinflammatory

3 terms

biopharmaceutical medical

"Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

immunotherapies medical

"next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

neuroinflammatory medical

"targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people"

Neuroinflammatory describes inflammation occurring in the brain, spinal cord or peripheral nerves when the body's immune response becomes active in nervous tissue. For investors, it matters because neuroinflammatory processes are central to many neurological diseases and can drive demand for new drugs, affect clinical trial outcomes, and influence regulatory decisions—similar to how a neighborhood dispute can change local services and property values, inflammation can reshape treatment needs and company prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., President and Chief Executive Officer, will present at the Bank of America Securities Health Care Conference 2026 on Wednesday, May 13, 2026 at 11:20 a.m. PT.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to millions of patients to help them live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Annexon (ANNX) present at the Bank of America Health Care Conference?

Annexon will present on Wednesday, May 13, 2026 at 11:20 a.m. PT. According to Annexon, Douglas Love, President and CEO, is scheduled to deliver the company presentation at that time during the conference.

How can I watch Annexon (ANNX) live at the May 13, 2026 presentation?

You can watch the live webcast via the company Investors page under Events & Presentations. According to Annexon, the webcast link is available on www.annexonbio.com for live viewing.

Will Annexon (ANNX) make the presentation replay available after the May 13, 2026 event?

Yes. A replay will be archived on the company website for 30 days following the presentation. According to Annexon, the replay will remain accessible in the Events & Presentations section.

Who will present for Annexon (ANNX) at the Bank of America Health Care Conference 2026?

Douglas Love, President and Chief Executive Officer, will present on behalf of Annexon. According to Annexon, he will represent the company and discuss its targeted immunotherapy platform aimed at neuroinflammatory diseases.

Where on Annexon's website can investors find the May 13, 2026 webcast for ANNX?

The webcast and replay are posted under the Events & Presentations section on the Investors page. According to Annexon, investors should visit www.annexonbio.com to access the webcast materials.